How Should Class IIb and Class III Devices Prepare for Australia TGA UDI Implementation?

Answer: For Class IIb and Class III medical devices supplied in Australia, preparation for the TGA UDI requirements should begin well before 1 July 2026. Manufacturers and Sponsors should confirm whether the device is in scope, assign and maintain UDI-DIs at the appropriate packaging levels, verify label space and data carrier feasibility, ensure the Sponsor can maintain AusUDID records, align ARTG information with UDI data, and assess whether existing EU or US UDI systems can be reused for Australia. UDI is not merely a barcode exercise; it is a compliance system linking registration, labelling, post-market traceability, recall and product data maintenance.

Article information

Published: 2026-07-08 09:00

Updated: 2026-07-08 09:00

This FAQ addresses priority questions that companies need to assess in international medical device registration, documentation preparation, compliance pathways and post-market maintenance.

Content structure

• Key summary
• Reference basis
• Suitable readers
• Regulatory assessment logic
• Documentation preparation priorities
• Operational steps for companies
• Common errors
• AIMEILI professional advice
• Internal checklist
• Continue reading
• Applicability boundaries

Key summary

From 1 July 2026, the Australian TGA will implement UDI requirements for certain medical devices, initially covering higher-risk Class IIb and Class III products. Companies need to confirm in advance whether their products are in scope, how UDI-DI and packaging levels should be set, whether label space is sufficient, whether the Sponsor can maintain AusUDID-related data, whether ARTG information and UDI data are consistent, and whether existing EU or US UDI systems can be reused for Australia. UDI is not simply affixing a code; it is a set of compliance requirements connecting registration, labelling, post-market traceability, recall and product data maintenance.

Reference basis

Official source: TGA

Source link: https://www.tga.gov.au/news/news-articles/new-udi-requirements-medical-devices-commence-1-july-2026

This article is prepared based on publicly available official information and AIMEILI international registration project experience. The specific pathway should still be determined according to the product risk class, intended use and the latest requirements of the regulatory authority.

Suitable readers

This content is suitable for medical device manufacturers, regulatory affairs professionals, overseas market managers and CRO teams preparing labelling, UDI and traceability projects. If a company already has Chinese, EU, US or other market documentation but is unsure whether it can be reused in the target market, it should also read this and complete a gap assessment before project launch.

Regulatory assessment logic

Companies should first confirm the product regulatory status, risk class, intended use, applicable regulatory pathway and local responsible entity, and then determine the required depth of documentation. TGA-related requirements generally do not examine a single document in isolation; they also assess whether product claims, technical evidence, labels and instructions for use, quality system and post-market responsibilities are consistent.

Documentation preparation priorities

It is advisable to build a documentation package covering product description, models and specifications, risk management, performance verification, clinical or evaluation evidence, quality system, labels and instructions for use, authorisation documents, UDI or traceability information, change management and post-market surveillance. For software, IVD, sterile, active and medium-to-high-risk products, additional specific evidence should be included.

Operational steps for companies

• Step 1: Establish a product and model list.
• Step 2: Reclassify products according to the target market.
• Step 3: Check the coverage of existing certificates and test reports.
• Step 4: Identify labelling, language, local representative and post-market obligations.
• Step 5: Prepare a gap list and supplementary documentation plan.
• Step 6: Then arrange translation, signing, submission and responses to review questions.

Common errors

Common errors include directly translating domestic documentation, ignoring the local responsible entity, relying excessively on existing CE or FDA documentation, unclear product model coverage, label claims beyond the evidence scope, and missing post-market surveillance and change control processes. What regulators really focus on is whether the evidence chain is closed, not the number of documents.

AIMEILI professional advice

AIMEILI recommends incorporating this issue into the registration project initiation assessment rather than supplementing documents only before submission. A more robust approach is to complete pathway assessment and documentation gap assessment first, and then manage the target country, product classification, document reuse, additional testing, local representative and post-market maintenance in a single project plan.

Internal checklist

• Are product classification, intended use and model scope clearly defined?
• Do existing certificates, test reports and technical files cover the intended submission scope?
• Are the responsibilities of the local representative, Sponsor or registration holder clearly defined?
• Have labels, instructions for use, UDI, language and post-market maintenance been planned?
• Has a documentation gap list and supplementary testing plan been prepared?
• Are official sources and applicability boundaries documented?

Continue reading

Previous: What can FDA medical device recall information reveal for Chinese export companies?

Next: Which submission strategies will be affected by the updated Singapore HSA medical device grouping registration guidance?

Recommended reading:

• What should companies prepare before TGA medical device registration in Australia?
• Can CE documentation be reused for Singapore HSA medical device registration?
• What core documents are required for UAE MOHAP medical device registration?
• Why is the ANVISA medical device registration cycle in Brazil so long?
• What is the difference between a Vietnam medical device import licence and registration certificate?
• How should a local agent for Indonesia medical device registration be selected?

Applicability boundaries

Source principle: Priority is given to official regulatory authorities, international organisations, standards organisations and publicly available regulatory materials; industry media and project experience are used only as supplementary judgment.

Applicability boundary: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country regulatory authority, testing conclusions or legal opinions.